T cell depletion for graft-versus-host-disease prophylaxis: a perspective on engraftment in mice and humans
DA Vallera, BR BLAzAR - Transplantation, 1989 - journals.lww.com
Transplantation, 1989•journals.lww.com
GRAFT-VERSUS-HOST"-DISEASE Allogeneic bone marrow transplantation has become a
viable clinical option for patients suffering from neoplastic or nonneoplastic hematologic
disorders (7). Marrow transplantation typically involves the use of highly aggressive
chemotherapy, with or without radiotherapy, to eradicate the aberrant lymphohematologic
system of the host. A saving dose of bone marrow from a normal donor is administered to
reestablish a functional hematologic and immunologic system.
viable clinical option for patients suffering from neoplastic or nonneoplastic hematologic
disorders (7). Marrow transplantation typically involves the use of highly aggressive
chemotherapy, with or without radiotherapy, to eradicate the aberrant lymphohematologic
system of the host. A saving dose of bone marrow from a normal donor is administered to
reestablish a functional hematologic and immunologic system.
GRAFT-VERSUS-HOST"-DISEASE Allogeneic bone marrow transplantation has become a viable clinical option for patients suffering from neoplastic or nonneoplastic hematologic disorders (7). Marrow transplantation typically involves the use of highly aggressive chemotherapy, with or without radiotherapy, to eradicate the aberrant lymphohematologic system of the host. A saving dose of bone marrow from a normal donor is administered to reestablish a functional hematologic and immunologic system.
Lippincott Williams & Wilkins